Finnegan attorneys Jennifer H. Roscetti and Erin M. Sommers participated in Managing Intellectual Property's European Life Sciences Forum, where they discussed patent eligibility and Section 101 in the United States, as well as inter partes review (IPR) proceedings in the life sciences industry.
They discussed tips for developing your claim and suggested learning from past Federal Circuit cases (such as Genetic Technologies v. Merial), particularly if "in looking at your claim, the patent office or a defendant in litigation can argue that your claim elements start and end with natural law of natural phenomenon and nothing more. Considering that law, if you have these methods that are routine in nature, they are likely to end up being ineligible subject matter." They also addressed the importance of communicating with the patent examiner to understand what you need to add to your claim for it to be considered eligible subject matter. Lastly, Roscetti and Sommers discussed the growing rate of biotech and pharmaceutical patents being challenged at the Patent Trial and Appeal Board (PTAB) and the potential impact of Oil States Energy Services LLC v. Greene's Energy Group, a case set to be heard by the U.S. Supreme Court that challenges the constitutionality of America Invents Act (AIA) proceedings.
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Apple Eyes Long-Term Software Fix for Watch While Appealing Ban
December 28, 2023
Award/Ranking
Asian Legal Business Names Finnegan “International IP Law Firm of the Year”
November 10, 2023
Award/Ranking
Five Finnegan Partners Named 2024 Leading Litigators in America by Lawdragon
October 30, 2023
Commentary
Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache
October 10, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.